Online citations, reference lists, and bibliographies.
← Back to Search

Ipilimumab In Combination With Paclitaxel And Carboplatin As First-Line Treatment In Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From A Randomized, Double-Blind, Multicenter Phase II Study

A. Tsao
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references



This paper is referenced by
Rôle de TLR7 dans la progression tumorale dans le cancer du poumon
Marion Dajon (2017)
10.1158/2326-6066.CIR-14-0124-T
PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer
A. Kloos (2015)
10.1111/imj.12653
Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities
C. Gedye (2015)
10.1158/1078-0432.CCR-14-1187
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
V. Anagnostou (2015)
10.1155/2015/847383
Evolving Concepts: Immunity in Oncology from Targets to Treatments
H. Khan (2015)
10.3109/0284186X.2015.1071918
Emerging immune checkpoints for cancer therapy
X. Li (2015)
10.1002/ijc.31012
The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta‐analysis of efficacy and safety
Yingcheng Wu (2017)
10.2147/OTT.S84356
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Y. L. Ang (2016)
10.1093/ckj/sfy100
Renal toxicities associated with pembrolizumab
H. Izzedine (2019)
Advancing targeted therapies—report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14–16 2013, Mainz, Germany
Mustafa Diken (2013)
10.2147/OTT.S111209
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
H. El-Osta (2016)
10.3978/j.issn.2218-6751.2015.12.11
Cancer stem cells and immunoresistance: clinical implications and solutions.
J. Codony-Servat (2015)
10.1186/1471-2407-12-580
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment
M. E. Heuvers (2012)
10.3389/fimmu.2015.00516
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
K. Kersten (2015)
10.1002/jcb.28250
Promising immunotherapy: Highlighting cytokine‐induced killer cells
S. Shirjang (2019)
10.1177/000313482008600423
Article Commentary: Cancer Immunotherapy for the General Surgeon
M. W. Fromer (2020)
10.1002/cam4.2112
Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective
P. Misra (2019)
10.1016/j.jtho.2016.05.027
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
F. Facchinetti (2016)
10.1080/2162402X.2015.1071008
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
B. Besse (2016)
10.3748/wjg.v22.i33.7440
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
S. Kimbara (2016)
10.1097/JTO.0b013e318286cf88
Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches
D. Spigel (2013)
Defining and targeting combination immunotherapies in mouse models of cancer
Franz Demane (2019)
10.1053/j.seminoncol.2015.05.007
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.
J. Wargo (2015)
10.1002/acm2.12728
Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response
C. Grassberger (2019)
10.1016/j.csbj.2015.03.008
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D Leone (2015)
10.1002/ijc.30678
Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data
Wenjun Wang (2017)
10.3109/1061186X.2013.830309
Efficacy of combined therapy with paclitaxel and low-level ultrasound in human chronic myelogenous leukemia cell line K562
Shuang Yang (2013)
10.3779/j.issn.1009-3419.2020.104.07
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC: A Meta-analysis and Systematic Review].
Qiaoxi Qin (2020)
10.2147/TCRM.S191022
Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
Y. Jiang (2019)
10.1002/cam4.1101
Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
P. Tan (2017)
10.1111/ajco.12361
Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors
T. John (2015)
10.1002/jcb.28754
Bioinformatics profiling utilized a nine immune‐related long noncoding RNA signature as a prognostic target for pancreatic cancer
Chunmi Wei (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar